Geriatric Assessment for Blood Disorders
Trial Summary
Will I have to stop taking my current medications?
The trial information does not specify if you need to stop taking your current medications. However, since the study includes a review of your current medications as part of the geriatric assessment, it's possible that adjustments might be recommended.
What data supports the effectiveness of the treatment Geriatric assessment (GA) pre-transplant for blood disorders?
Research shows that using geriatric assessment (GA) before transplants helps doctors better understand the overall health of older patients, which can lead to more personalized and effective treatment plans. This approach has been shown to improve the quality of care and outcomes for older adults with blood disorders by identifying health issues that might not be obvious and tailoring treatments to individual needs.12345
Is geriatric assessment generally safe for humans?
How does the geriatric assessment treatment differ from other treatments for blood disorders?
Geriatric assessment (GA) is unique because it evaluates the overall health and functional status of older patients before a transplant, allowing doctors to tailor treatments to individual needs. This approach helps identify hidden health issues, improve treatment outcomes, and reduce side effects, unlike standard treatments that may not consider these factors.1231011
What is the purpose of this trial?
This study will evaluate whether a geriatric assessment can lead to better treatment outcomes in older patients (age 60+) with a myeloid malignancy including acute myeloid leukemia, ,myelodysplastic syndromes, myeloproliferative neoplasms, or related blood disorders who are going to receive chemotherapy or another treatment to prepare the body for an allogeneic hematopoietic stem cell transplant (allo-HCT). The geriatric assessment includes looking at patients' cognitive function (thinking processes), physical function, mobility (ability to move the body), mood, nutrition, and current medications to help decide the type of treatment they'll receive.Another purpose of this study is to see whether use of the geriatric assessment improves participants' quality of life. We will evaluate participants' quality of life through questionnaires.
Research Team
Richard j Lin, MD, PhD
Principal Investigator
Memorial Sloan Kettering Cancer Center
Eligibility Criteria
This trial is for people aged 60 or older with certain blood disorders like acute myeloid leukemia and related conditions, who have a suitable donor for stem cell transplant. They must meet the standard criteria for transplantation and have less than 10% of immature cells (blasts) in their bone marrow.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Geriatric Assessment
Participants undergo a geriatric assessment to evaluate cognitive function, physical function, mobility, mood, nutrition, and current medications to determine treatment approach
Treatment
Participants receive risk-adapted conditioning regimens (MA or RIC/NMA) based on geriatric assessment, including chemotherapy and possibly radiation therapy
Follow-up
Participants are monitored for safety, effectiveness, and quality of life through questionnaires after treatment
Treatment Details
Interventions
- Geriatric assessment (GA) pre-transplant
Find a Clinic Near You
Who Is Running the Clinical Trial?
Memorial Sloan Kettering Cancer Center
Lead Sponsor